Kite's Yescarta (axicabtagene ciloleucel) first CAR T-cell therapy to receive Health Canada authorisation for use in second-line large B-cell lymphoma

Gilead

23 March 2023 - Landmark ZUMA-7 study demonstrated patients on Yescarta were 2.5 times more likely to be alive at 18 months without cancer progression or need for additional cancer treatment.

Gilead Canada and Kite today announced they have received a Health Canada Notice of Compliance for Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor T-cell therapy for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Read Gilead press release

Michael Wonder

Posted by:

Michael Wonder